Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elad Sharon

Showing results (141-150 of 191) with videos related to

Pageof 20
Sort By:
Radiation Research|October 12, 2020
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?Pataje G Prasanna, Gayle E Woloschak, Andrea L DiCarlo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancerThatcher Ross Heumann, Jiayun Lu, Hao Wang, et al.
Nature Medicine|February 12, 2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapyAarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Spatial Transcriptomics Identify T Cell-Driven Mechanisms of Kidney Damage in Immune Checkpoint Inhibitor-Associated Acute Interstitial NephritisQian Qin, Lennard Ostendorf, Sophia L Wells, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.
Clinical Pharmacology and Therapeutics|October 19, 2021
The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case StudiesDonna R Rivera, Henry J Henk, Elizabeth Garrett-Mayer, et al.
Medrxiv : the Preprint Server for Health Sciences|March 23, 2026
An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation studyJack Gallifant, Shan Chen, Kee-Young Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian CancerYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
NPJ Breast Cancer|December 30, 2022
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013Foluso O Ademuyiwa, Feng Gao, Cherease R Street, et al.
Pageof 20

Showing results (141-150 of 191) with videos related to

Sort By:
Pageof 20
Radiation Research|October 12, 2020
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?Pataje G Prasanna, Gayle E Woloschak, Andrea L DiCarlo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancerThatcher Ross Heumann, Jiayun Lu, Hao Wang, et al.
Nature Medicine|February 12, 2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapyAarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Spatial Transcriptomics Identify T Cell-Driven Mechanisms of Kidney Damage in Immune Checkpoint Inhibitor-Associated Acute Interstitial NephritisQian Qin, Lennard Ostendorf, Sophia L Wells, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.
Clinical Pharmacology and Therapeutics|October 19, 2021
The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case StudiesDonna R Rivera, Henry J Henk, Elizabeth Garrett-Mayer, et al.
Medrxiv : the Preprint Server for Health Sciences|March 23, 2026
An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation studyJack Gallifant, Shan Chen, Kee-Young Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian CancerYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
NPJ Breast Cancer|December 30, 2022
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013Foluso O Ademuyiwa, Feng Gao, Cherease R Street, et al.
Pageof 20